Fear Free^s

In-Hospital Pharmaceuticals



Class & Action: Sedatives

DRUG	DOSAGE	ADVANTAGES	DISADVANTAGES	NOTES	CONTRAINDICATIONS
acepromazine	Dog: 0.01-0.03 mg/kg IV or IM (up to 0.2 mg/kg IM); Cat: 0.03- 0.05 mg/kg IV or IM (up to 0.2 mg/kg IM); these dosages can be used alone or in combination with alpha-2 agonists or benzodiazepines	mild to moderate sedation that lasts several hours; can be given orally or transmucosally but higher (see transmucosal chart for more information) doses will be required & onset of effects are slow	only mild to moderate sedation; not anxiolytic; not analgesic; not reversible; duration may be longer than desired; effects not predictable from one patient to another	If anxiolysis rather than sedation is required, a benzodiazepine should be added to the protocol	no absolute contraindications but use with caution in patients with hepatic disease, clotting dysfunction, or hypotension; recent evidence proves that acepromazine does NOT cause seizures
alfaxalone	Cats & Small Dogs: 0.5-1.0 mg/kg IM, PLUS Opioid Mild pain: 0.2-0.4 mg/kg butorphanol, 0.02-0.03 mg/kg buprenorphine IM or IV	can be administered IM as part of sedation protocols, particularly in cats and small dogs; less cardiac effects than alpha-2 agonists; shorter duration than acepromazine	no reversal agent, no analgesia; volume limits IM administration to small patients (cats and small dogs); must combine with other sedatives and/or analgesic drugs to avoid rough inductions and recoveries	alfaxalone is primarily used as an IV induction drug but can be used as part of a sedation protocol; sedation level is generally light to moderate; commonly administered with opioids	no absolute contraindications

Class & Action: Alpha-2 agonists; Sedative-analgesics

DRUG	DOSAGE	ADVANTAGES	DISADVANTAGES	NOTES	CONTRAINDICATIONS
dexmedetomidine	for light to moderate sedation: Dog: 1.0-3.0 microg/kg IV or 3.0- 10.0 microg/kg IM; Cat: 1.0-5.0 microg/kg IV or 5.0- 15.0 microg/kg IM; for profound sedation: Dog- 8.0- 28.0 microg/kg IV or 12-40 microg/kg IM; Cat-20-40 microg/kg IM; DECREASE DOSAGES IF USED WITH OPIOIDS; use low end of dosing range for older patients, low level of FAS, & when used with opioid; high end range for younger patients, higher level of FAS or when used solo	rapid onset; can be given IM; titratable sedation from mild to profound; decrease stress; provide analgesia & sedation; reversible	cardiovascular effects including hypertension and increased cardiac work due to vasoconstriction; patient can suddenly react to painful stimulus even when deeply sedated	most predictable effects when used in combination with other drugs to avoid sudden arousal; generally the best drugs for patients exhibiting moderate to profound FAS and/or aggression; the dosages in this chart are based on FDA approved dosages however there are no FDA approved IV dosages for cats; see the product insert for more information	do not use in patients with cardiovascular disease
medetomidine	Dosages are exactly double the microg/kg dexmedetomidine dosages				

DRUG	DOSAGE	ADVANTAGES	DISADVANTAGES	NOTES	CONTRAINDICATIONS
midazolam	Dog or Cat: 0.1 -0.2 mg/kg IM or IV	injectable; fast acting; minimal to no adverse physiologic effects;	reversal may cause arousal in some; not potent sedation; may	due to possible paradoxical excitation, use in combination with a true sedative for those	none
diazepam	Dog or Cat: 0.1-0.2 mg/kg IV only	enhance calming when used in combination with true sedatives; midazolam can be given IM	not be not effective if patient is already exhibiting FAS and/or aggression; possible paradoxical excitation	exhibiting FAS and/or aggression	

Class & Action: Opioids; Analgesics

DRUG	DOSAGE	ADVANTAGES	DISADVANTAGES	NOTES	CONTRAINDICATIONS
butorphanol;	Low Pain	mild to potent	may cause	combine with a	no absolute
buprenorphine	butorphanol	analgesia	vomiting; slow GI	sedative to avoid	contraindications; use
	Dog & Cat- 0.2-0.4 mg/kg IM or IV;	depending on the	motility;	excitement in cats;	with caution in patients
	buprenorphine	drug; wide safety	decrease in	with mild pain use	in which vomiting
	Dog & Cat- 0.02-0.03 mg/kg IM or IV	margin; fast onset	respiratory	butorphanol or	would be detrimental;
		except	function with	buprenorphine;	use with caution in
		buprenorphine;	inhalant	with moderate to	patients with existing
hydromorphone;	High Pain	reversible; many to	anesthesia; more	severe pain use	respiratory depression
methadone;	hydromorphone:	choose from;	potent opioids	hydromorphone,	
morphine	Dog- 0.1-0.2 mg/kg IM or IV; Cat - 0.1	variety of routes of	may cause	methadone, or	
	mg/kg IM or IV;	administration;	excitement in	morphine	
	methadone: Dog- 0.3-0.5 mg/kg IM or	synergistic with	cats		
	IV; Cat- 0.3 mg/kg IM or IV;	sedatives			
	morphine: Dog - 0.3-1.0 mg/kg IM;				
	Cat - 0.1-0.3 mg/kg IM				

Class & Action: Dissociative anesthetic drugs; Immobilizers

DRUG	DOSAGE	ADVANTAGES	DISADVANTAGES	NOTES	CONTRAINDICATIONS
ketamine	Dog & Cat: 1.0-2.0 mg/kg IM when used in combination with a sedative may provide dissociation without anesthesia while the same dose IV will provide light anesthesia; 5.0-10.0 mg/kg IM for true anesthesia; IM good route for cats; volume at this dose may be too high for large sized dogs	decrease CNS response to circulating neurotransmitters in those already exhibiting FAS and/or aggression; decreases incidence of sudden arousal to stimulus	administration can produce anesthesia so patients should be monitored; duration may be longer than desired; not reversible; ketamine is painful on injection; prolonged, rough recoveries are possible with tiletamine- zolazepam, especially in dogs	cleared by the liver & kidneys	no absolute contraindications; use with caution in patients with sympathetically driven cardiac arrhythmias or seizures; use with caution in patients with diagnosed hepatic or renal disease
tiletamine- zolazepam	Dog & Cat: 1.0-2.0 mg/kg IM				

Pharmaceutical Use and Owner Consent

Not all of the drugs in these charts are FDA-approved for use in dogs and cats. Drugs like the alpha-2 agonists and acepromazine are often used at **lower** than the FDA-approved dose as profound sedation is not always necessary. However, all of the dosages in this chart are commonly used in practice and are referenced in the veterinary literature.

The AVMA Policy on Owner Consent states that veterinarians or staff should provide sufficient information in a form and manner that enables owners or their authorized agents to make appropriate decisions when choosing the veterinary care provided. An assessment of risks and benefits of recommended treatments should be provided. In response owners or their authorized agents should indicate:

- Their questions have been answered to their satisfaction
- The information received by them has been understood
- They are consenting to the recommended treatments

The consent can be verbal or written and should be documented in the medical record by the veterinarian or staff member.

Taken from the AVMA Policy on Owner Consent in Veterinary Medicine. You should review the complete policy here: https://www.avma.org/KB/Policies/Pages/Owner-Consent-in-Veterinary-Medicine.aspx